TD Cowen raised the firm’s price target on MDxHealth to $8 from $7 and keeps an Outperform rating on the shares. The firm said they are a materially different company than a year ago with 3 prostate tests on market and Medicare reimbursed as well as a UTI test.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDXH:
